New product launch: UltraBLIS(TM)
Blis Technologies Limited: 81 Glasgow Street, South Dunedin 9012, PO Box 2208, Dunedin 9012, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz
3 February 2020
New product launch: UltraBLIS™
Dunedin based Blis Technologies has launched a new product UltraBLIS which is a unique
combination of BLIS K12™ with two gut probiotic strains.
UltraBLIS is a next generation probiotic supplement targeted at those wanting to optimise their
microbiome and strengthen overall immunity. BLIS K12 has strong evidence
in the oral microbiome,
and it has been combined in a lozenge format with Bifidobacterium lactis HN019 (HOWARU®), and
Lactobacillus acidophilus La‐14: 2 strains from Dupont® that have strong evidence bases in
immunity.
The product will initially be available exclusively online from www.ultrablis.co.nz with planning for a
NZ retail launch underway.
For more information on the product and for purchase please visit www.ultrablis.co.nz.
Ends
For further information, please contact:
Julie Curphey
Chief Marketing Officer
+64 21 344 527
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation
with evidence-based research and the highest quality production controls enables the delivery of probiotic
solutions for specific health targets including throat health, halitosis (bad breath), immune support and teeth and
gum health. BLIS products are sold throughout New Zealand and in Australia, Asia, Europe and the USA. More
information about Blis Technologies Ltd can be found at www.blis.co.nz.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- PEB — Pacific Edge Limited: Pacific Edge FY20 Interim Results and Capital Raising2019-11-20
“Company Announcement 21 November 2019 6 The USA remains the primary commercial opportunity for Pacific Edge, with a growing number of very large and reputable healthcare providers and academic centres such as Johns Hopkins Medicine, Cleveland Clinic and Moun…”
- PEB — Pacific Edge Limited: Real World Evidence Highlights Clinical Utility of Cxb2020-02-11
“Company Announcement 12 February 2020 For more information contact: David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800 OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed,…”
- PEB — Pacific Edge Limited: PEB TO CONTINUE PROVIDING ESSENTIAL DIAGNOSTIC SERVICES2020-03-24
“Company Announcement 25 March 2020 For more information contact: David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800 OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer…”